Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance
October 27, 2015 02:00 ET
|
NOVARTIS FINANCE S.A.
Solid growth (cc[1]) in Q3 sales, core operating income, core EPS for continuing operations[2] Net sales were USD 12.3 billion (-6%, +6% cc) Operating income was USD 2.2 billion (-18%, +2% cc)...
Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis
October 23, 2015 07:25 ET
|
NOVARTIS FINANCE S.A.
Cosentyx (secukinumab) is recommended for approval in Europe for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients Cosentyx demonstrated rapid onset of action...
Novartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approval
September 25, 2015 01:15 ET
|
NOVARTIS FINANCE S.A.
Positive opinion from EU review body puts Entresto on track to be approved for HFrEF patients across Europe likely by year end Entresto was studied in world's largest heart ...
Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires
September 24, 2015 12:00 ET
|
NOVARTIS FINANCE S.A.
New leader to continue to drive long-term innovation in Novartis research in wide range of therapeutic areas Basel, September 24, 2015 - Novartis announced today that Dr. James (Jay) E....
Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches
July 21, 2015 01:00 ET
|
NOVARTIS FINANCE S.A.
Sales, core[1] operating income and core EPS grew (cc[1]) for continuing operations[2] in Q2: Net sales amounted to USD 12.7 billion (-5%, +6% cc) Operating income was USD...
Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization
July 07, 2015 16:33 ET
|
NOVARTIS FINANCE S.A.
First in the world approval brings hope of longer life and fewer hospitalizations for millions of Americans with heart failure with reduced ejection fraction Entresto is the first and only...
Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolio
April 23, 2015 01:00 ET
|
NOVARTIS FINANCE S.A.
Continuing operations[1] saw sales, core[2] operating income and core EPS grow (cc[2]) in Q1 Net sales were USD 11.9 billion (-7%, +3% cc)[2] Operating income was USD 2.8 billion (-1%, +15% cc)...
Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg
April 16, 2015 12:26 ET
|
NOVARTIS FINANCE S.A.
Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Novartis and Sandoz are driving access to a full range of...
FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz
March 06, 2015 09:10 ET
|
NOVARTIS FINANCE S.A.
Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the...
Novartis' heart failure medicine LCZ696 granted FDA priority review
February 13, 2015 11:30 ET
|
NOVARTIS FINANCE S.A.
Decision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8 months Filing is based on results from the landmark PARADIGM-HF study[1] Nearly...